MAGPIE
2002
Magnesium Sulphate for Prevention of Eclampsia trial
In 10,141 women with pre-eclampsia before delivery or shortly afterwards, magnesium sulphate halved the risk of eclamptic convulsions compared with placebo, without reducing perinatal death.
Result
- Absolute difference
- 1.1 points
- NNT
- 91
lower risk5895% CI 40-71
Absolute difference and NNT are derived from the event rates.
Also reported: No clear difference in death of the baby (12.7 % vs 12.4 %). Side effects, mainly flushing, in 24 % vs 5 %.
- Subtopic
- Eclampsia prevention
- Design
- International, placebo-controlled RCT in 33 countries
- Relevance
- Practice-defining: a trial the field needs to know.
- Source
- Altman D, Carroli G, Duley L, et al. Lancet. 2002;359(9321):1877-1890.doi 10.1016/S0140-6736(02)08778-0
Discussion & critique
The absolute benefit is modest where baseline eclampsia rates are low, a quarter of treated women had side effects, and perinatal death was unchanged. But with 10,141 women across 33 countries it settled the question definitively: magnesium sulphate, not phenytoin or diazepam, is the anticonvulsant of choice in pre-eclampsia.